Related Experiment Video
Updated: Aug 13, 2026

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
Published on: March 19, 2019
Combating opportunistic infections: coccidioidomycosis
1University of Arizona, Southern Arizona Veterans Affairs Medical Center, Tucson, AZ 85723, USA. nampel@u.arizona.edu
Abstract:
Coccidioidomycosis is a growing problem in the southwestern US. Although most cases of symptomatic coccidioidomycosis occur in healthy individuals, individuals with depressed cellular immunity are at particular risk. These include individuals with HIV infection, those who have undergone allogeneic transplantation and others on immunosuppressive medications. Most instances of primary pulmonary coccidioidomycosis do not require antifungal therapy. However, almost all cases of disseminated coccidioidomycosis will require such therapy. The triazole antifungals, fluconazole and itraconazole, are effective therapies for coccidioidomycosis. Amphotericin B is now reserved for severe or recalcitrant cases. Coccidioidal meningitis requires lifelong therapy with triazole antifungals. Intrathecal amphotericin B is required for those cases that fail. Prevention of coccidioidomycosis by environmental control is difficult. In the future, immunisation or immune modulation may offer protection.
More Related Videos
Related Concept Videos
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Fungal Phylum Microsporidia
Cryptococcal Meningitis
Candidiasis
Antifungal Agents

